We note this hypothesis leads to a clinical prediction: the large size of the conserved EGFR-mut interactome is consistent with clinical observations that targeted therapy blocking the EGFR-mut oncogenic signal profoundly decreases the fitness of individual tumor cells. This evidence concerns the gene EGFR and neoplasm.